Countries covered: Global
This report analyzes the worldwide markets (Annual Revenues) for Lung Cancer Therapeutics in Millions of US$. The US market for Non-Small Cell Lung Cancer treatment is further analyzed by: Chemotherapy Drugs, and Targeted Drugs. The report provides separate comprehensive analytics for the US, Europe and Rest of World. Annual forecasts are provided for each region for the period 2005 through 2015. The report profiles 191 companies including many key and niche players worldwide such as AstraZeneca PLC., Bristol-Myers Squibb Co., Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline Plc., Novartis Pharmaceuticals Corporation, OSI Pharmaceuticals, Inc., Sanofi-Aventis, AbGenomics International Inc., ImClone Systems, Inc., Pfizer, Inc., Merck Serono International S.A., Merck & Co. Ltd., Telik, Inc., and Woomera Therapeutics, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Titles available via "online download" are not affected by this and are still delivered to your reading room immediately.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
|
- I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- Chemotherapy Drugs
- Targeted Drugs
- II. EXECUTIVE SUMMARY
- 1.MARKET OVERVIEW
- Lung Cancer Therapeutics - Driven by Next Generation Drugs
- New Therapies Drive NSCLC Market
- Market Value of Taxanes to Decrease by 2015
- Lung Cancer - The Killer Disease
- Lung Cancer - A Quick Glance at Global Statistics
- Asia Heading for Possible Lung Cancer Epidemic
- Table 1: Global Incidence of Lung Cancer (2008): Percentage Share Breakdown by Region (includes corresponding Graph/Chart)
- 2.LUNG CANCER - AN INSIGHT
- Lungs - Critical for Oxygen Supply
- Lung Cancer - An Introduction
- Common Symptoms of Lung Cancer
- Types of Lung Cancer
- Non-Small Cell Lung Cancer
- NSCLC - At a Glance
- Small Cell Lung Cancer
- Risk Factors for Lung Cancer
- Female Smokers at Higher Risk of DevelopingLung Cancer
- Lung Cancer Diagnostics
- Lung Cancer Staging
- Staging for Non-Small Cell Lung Cancer
- Staging for Small Cell Lung Cancer
- 3.LUNG CANCER TREATMENT MODALITIES
- Surgery
- Radiation Therapy
- Chemotherapy
- Combination Therapy
- Photodynamic Therapy
- Vaccines
- Common Treatment Modalities for SCLC and NSCLCLung Cancers
- Pain Management
- 4.INTRODUCTION TO LUNG CANCERTHERAPEUTICS
- Chemotherapy
- Drug Administration
- Overview of Chemotherapy Regimens and Drugs
- Side Effects of Chemotherapy
- Targeted Therapy
- Chemotherapy Drugs for SCLC Treatment
- Chemotherapy Drugs for NSCLC Treatment
- Major Chemotherapy Drugs
- Select Chemotherapy Drugs Used in the Treatment ofLung Cancer by Brand and Generic Name
- Overview of Select Chemotherapeutic Drugs
- Alimta
- Carboplatin and Cisplatin
- Docetaxel
- Paclitaxel
- Xyotax
- Gemcitabine
- Gefitinib
- Irinotecan
- Vinorelbine (Navelbine®)
- 5.PRODUCT DEVELOPMENT IN NSCLCTHERAPEUTICS
- R&D Focus in NSCLC Treatment
- Drug Development Process - Growth Opportunities &Challenges
- Product Pipeline for NSCLC Treatment
- Product Pipeline for NSCLC Treatment
- Select (Ongoing/Completed) Clinical Trials forNSCLC Treatment
- Companies Focus on Molecular Targeted Therapies
- Molecular Targeted Therapies - Overview of SelectProduct Candidates
- Aflibercept (VEGF-Trap) - Sanofi Aventis/Regeneron
- BIBW 2992 - Boehringer Ingelheim
- Erbitux (cetuximab) - ImClone/Merck Serono/Bristol-Myers Squibb
- Nexavar (sorafenib) - Bayer Schering
- Recentin (cediranib) - AstraZeneca
- Sutent (sunitinib) - Pfizer
- Zactima (vandetanib) - AstraZeneca
- Zolinza (vorinostat) - Merck & Co
- Pipeline for Cytotoxic Therapy - Overview of SelectProducts
- Abraxane (albumin-bound paclitaxel) - Abraxis
- Glutoxim (NOV-002) - Novelos
- Javlor (vinflunine) - Pierre Fabre
- Lipoplatin (liposomal cisplatin) - Regulon
- Xyotax (paclitaxel polyglumex) - Cell Therapeutics/Novartis
- 6.PRODUCT APPROVALS/INNOVATIONS/LAUNCHES
- Intas Biopharmaceuticals to Introduce Gefitinib in India
- Celgene Receives FDA Fast Track Product Designationfor Amrubicin
- EMEA Approves ALIMTA for First-Line Therapy ofAdvanced NSCLC
- Celgene’s Cancer Drug Receives Orphan Drug Statusfrom European Commission
- Alimta Receives FDA Approval
- Roche Receives Approval from European Authoritiesfor Avastin
- OSI Pharmaceuticals Introduces Tarceva in Japan
- Shanghai Medipharm Introduces TNT Antibody forTreating Lung Cancer
- Natco Pharma Unveils an Injectible Drug forLung Cancer, Pemnat
- Roche Scientific Introduces Tarceva in the Indian Market
- GlaxoSmithKline’s HYCAMTIN® Receives MarketingApproval from EC
- Genzyme Launches New Genetic Mutation Test to AidLung Cancer Treatment
- UT Southwestern Medical Center Researchers DiscoverNew Anti-Cancer Drug
- Agennix's Talactoferrin Alfa Program Obtains Fast TrackDesignation from FDA
- Novelos Therapeutics’ NOV-002 Receives Fast TrackDesignation from FDA
- 7.RESEARCH & CLINICAL TRIALS
- Novartis Commences Phase III Clinical Trial of ASA404
- Results of BR.21 Trials
- Genentech Announces Results of Phase III BETALung Trial
- Results of SATURN Clinical Trial
- Results of Zactima’s Clinical Trials
- Results of Erbitux’s Phase III Trials
- Results of Roche’s AVAiL Clinical Trial
- GlaxoSmithKline Conducts Phase III Clinical Trial ofLung Cancer Vaccine
- FASgen Announces Research Results of FAS093
- The Cuban Regulatory Agency Registers a NewTherapeutic Lung Cancer Vaccine
- Gemin X Commences Clinical Trials of GX15-070
- Antisoma and Biomira Announce Clinical Trial Resultsof Lung Cancer Drugs
- OSI Pharmaceuticals Commences Phase III Clinical Trialsof Tarceva®
- Northwest Gets FDA Clearance to Conduct Clinical Trialsfor Lung Cancer Vaccine
- University of Kentucky Conducts Clinical Trials onLung Cancer Vaccine
- Poniard Enrolls in Phase II Small Cell Lung CancerClinical Trials of Picoplatin
- Sunesis Pharmaceuticals Starts Phase II Clinical Trialsof SNS-595
- Ligand Pharmaceuticals Tables Clinical Results ofTargretin®
- Bayer and Onyx Start Phase III Trial of Nexavar®
- Abraxis Announces Clinical Results of ABRAXANE®
- Introgen Conducts Phase II Clinical Trials of INGN 225
- YM BioSciences Commences Clinical Trial of Nimotuzumab
- 8.RECENT INDUSTRY ACTIVITY
- Merck Agrees to Merge with Shering-Plough
- Abbott Molecular Signs Agreement with Genentech, OSIand Roche
- IMUC Acquires Monoclonal Antibody Technologyfrom MDC
- Quest PharmaTech Enters into Collaboration with BCCancer Agency
- Daiichi Sankyo Acquires U3 Pharma
- MacroGenics Takes Over Raven Biotechnologies
- Roche Acquires Piramed
- Bristol-Myers Squibb Acquires Kosan Biosciences
- Point Therapeutics and DARA Biosciences Ink MergerAgreement
- Celgene Acquires Pharmion
- Pfizer to Takeover Serenex
- ATS Acquires Majority Stake in GANYMEDPharmaceuticals
- NCCN, AstraZeneca and Abraxis Enter into Collaboration
- Eli Lilly Agrees to Take Over ImClone Systems
- CytRx Takes Over Innovive Pharmaceuticals
- Abbott Extends Discovery Partnership with Caprion
- Bristol-Myers and ImClone to Expand the ClinicalDevelopment Program for ERBITUX
- Biomoda and New Mexico Tech Enter intoa Collaborative Agreement
- Binex Inks Sponsored Research Agreement with MaxCyte
- Simcere Pharmaceutical Acquires Master Luck
- Dako Enters into Collaboration with OSI, Roche, andGenentech
- Biomira and Merck Sign Revised Supply andCollaboration Agreements
- ImClone Systems Terminates Development Agreementwith UCB
- Astellas Pharma’s US Subsidiary Acquires Agensys
- Antisoma Enters into an Agreement with Novartis
- Pharmacyclics Files NDA for Xcytrin® Injection
- 9.FOCUS ON SELECT GLOBAL PLAYERS
- AstraZeneca PLC (UK)
- Bristol-Myers Squibb Co. (US)
- Eli Lilly & Co. (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Genentech, Inc. (US)
- GlaxoSmithKline Plc (UK)
- Novartis Pharmaceuticals Corporation (US)
- OSI Pharmaceuticals, Inc. (US)
- Sanofi-Aventis (France)
- Companies with Pipeline Drugs
- AbGenomics International Inc. (US)
- ImClone Systems, Inc. (US)
- Pfizer, Inc. (US)
- Merck Serono International S.A. (Switzerland)
- Merck & Co. Ltd. (US)
- Telik, Inc. (US)
- Woomera Therapeutics, Inc. (US)
- 10.GLOBAL MARKET PERSPECTIVE
- Table 2: World Recent Past, Current & Future Analysis forNon-Small Cell Lung Cancer Therapeutics Market byGeographic Region - US, Europe and Rest of World Independently Analyzed with Annual Revenues inUS$ Million for Years 2005 through 2015 (includescorresponding Graph/Chart)
- Table 3: World 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics by Geographic Region - Percentage Breakdown of Annual Revenues for US, Europe and Restof World Markets for Years 2006, 2009 & 2015(includes corresponding Graph/Chart)
- III. MARKET
- 1.THE UNITED STATES
- A. Market Analysis
- NSCLC Drug Market to Rise Sharply
- Lung Cancer Prevalence
- A Major Cause of Death among US Women
- Statistics
- Market Scenario
- FDA Places New Restrictions on Iressa
- Innovative Technology Enables Early Diagnosisof Lung Cancer
- Avastin to Emerge as the Preferred NSCLCDrug in the US
- Product Approvals/Clinical Trials/Introductions/Launches
- Strategic Corporate Developments
- Key Players
- B. Market Analytics
- Table 4: US Recent Past, Current & Future Analysis forNon-Small Cell Lung Cancer Therapeutics by Segment - Chemotherapy Drugs and Targeted Drugs Markets Independently Analyzed with Annual Revenues inUS$ Million for Years 2005 through 2015(includes corresponding Graph/Chart)
- Table 5: US 10-Year Perspective for Non-Small CellLung Cancer Therapeutics by Segment - Percentage Breakdown of Annual Revenues for ChemotherapyDrugs and Targeted Drugs Markets forYears 2006, 2009 & 2015
- 2.EUROPE
- A. Market Analysis
- Lung Cancer Therapeutics Market to WitnessRobust Growth
- Product Approvals
- Clinical Trials
- B. Market Analytics
- Table 6: European Recent Past, Current & FutureAnalysis for Non-Small Cell Lung Cancer Therapeuticsby Geographic Region - France, Germany, Italy, UKand Rest of Europe Independently Analyzed with Annual Revenues in US$ Million for Years 2005 through2015 (includes corresponding Graph/Chart)
- Table 7: European 10-Year Perspective for Non-SmallCell Lung Cancer Therapeutics Market by Geographic Region - Percentage Breakdown of Annual Revenuesfor France, Germany, Italy, UK and Rest of EuropeMarkets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
- 2a.FRANCE
- A. Market Analysis
- Overview of Lung Cancer Market
- Key Player
- B. Market Analytics
- Table 8: French Recent Past, Current & Future Analysisfor Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million forYears 2005 through 2015 (includes corresponding Graph/Chart)
- 2b.GERMANY
- A. Market Analysis
- Lung Cancer Scenario
- Chemotherapy Gains Preference
- Strategic Corporate Developments
- B. Market Analytics
- Table 9: German Recent Past, Current & Future Analysisfor Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million forYears 2005 through 2015 (includes corresponding Graph/Chart)
- 2c.ITALY
- A. Market Analysis
- Incidence in Women on Rise
- Treatment
- B. Market Analytics
- Table 10: Italian Recent Past, Current & Future Analysisfor Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million forYears 2005 through 2015 (includes corresponding Graph/Chart)
- 2d.THE UNITED KINGDOM
- A. Market Analysis
- British Women at Higher Risk
- Fast Facts
- Proposed Cancer Care Improvements Mulled byBritish Government
- NICE Recommends Use of Erlotinib in NSCLCTreatment
- Strategic Corporate Developments
- Key Players
- B. Market Analytics
- Table 11: UK Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005through 2015 (includes corresponding Graph/Chart)
- 2e.REST OF EUROPE
- A. Market Analysis
- Outlook
- Strategic Corporate Developments
- Key Player
- B. Market Analytics
- Table 12: Rest of Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$Million for Years 2005 through 2015 (includescorresponding Graph/Chart)
- 3.REST OF WORLD
- A. Market Analysis
- Australia
- Fast Facts
- Brazil
- China
- Overview of NSCLC Drug Market
- India
- Japan
- Product Launches
- Strategic Corporate Development
- B. Market Analytics
- Table 13: Rest of World Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$Million for Years 2005 through 2015 (includescorresponding Graph/Chart)
- IV. COMPETITIVE LANDSCAPE
- Total Companies Profiled: 191 (including Divisions/Subsidiaries - 200)
- Region/Country Players
- The United States
- Canada
- Japan
- Europe
- France
- Germany
- The United Kingdom
- Italy
- Rest of Europe
- Asia-Pacific (Excluding Japan)
More Global Oncology/Hematology Reports
2012 Global CA Tumor Markers Diagnostics Market Outlook: Test Volumes, Sales Forecasts, and Supplier Shares by Country by
Venture Planning Group
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific ...
2012 World Cancer Diagnostic Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country by
Venture Planning Group
This report provides a worldwide overview of the cancer diagnostics market, including mortality statistics and scientific views on the etiology of major types of cancer, ...
Cancer Pain Global Clinical Trials Review, H1, 2012 by
GlobalData
Cancer Pain Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Cancer Pain Global Clinical Trials Review, H1, 2012 provides data on the Cancer Pain ...
The 2012 Global Cancer Diagnostic Market Overview - Facilities, Test Volumes, and Sales Forecasts by Country by
Venture Planning Group
This report provides a worldwide overview of the cancer diagnostics market, including mortality statistics and scientific views on the etiology of major types of cancer, ...
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments) by
Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological ...
See all reports like this >>
Share this report
Other tasks Related Markets Oncology/Hematology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
